ERN1 and Miyoshi myopathy: Sunitinib, which is an FDA-approved anticancer drug and a type I inhibitor of the IRE1α kinase domain, effectively diminished splicing of XBP1 mRNA in H929 and U266 MM cell lines treated with an ER-stress activator tunicamycin.